The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses

References

• Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol Res 2008; 42:219-32; PMID:19066740; http://dx.doi.org/10.1007/s12026-008-8076-3
   PubMed Web of Science ®Google Scholar
• Babiuk S, Baca-Estrada ME, Foldvari M, Storms M, Rabussay D, Widera G, Babiuk LA. Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine 2002; 20:3399-408; PMID:12213410; http://dx.doi.org/10.1016/S0264-410X(02)00269-4
   PubMed Web of Science ®Google Scholar
• Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, Ishii KJ. Novel Strategies to Improve DNA Vaccine Immunogenicity. Curr Gene Ther 2011; 11; PMID:22023477
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: an historical perspective and view to the future. Immunol Rev 2011; 239:62-84; PMID:21198665; http://dx.doi.org/10.1111/j.1600-065X.2010.00980.x
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008; 26:2100-10; PMID:18378365; http://dx.doi.org/10.1016/j.vaccine.2008.02.033
   PubMed Web of Science ®Google Scholar
• Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993; 90:11478-82; PMID:8265577; http://dx.doi.org/10.1073/pnas.90.24.11478
   PubMed Web of Science ®Google Scholar
• Aihara H, Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998; 16:867-70; PMID:9743122; http://dx.doi.org/10.1038/nbt0998-867
   PubMed Web of Science ®Google Scholar
• Babiuk S, van Drunen Littel-van den Hurk S, Babiuk LA. Delivery of DNA vaccines using electroporation. Methods Mol Med 2006; 127:73-82; PMID:16988447
   PubMedGoogle Scholar
• Heller LC, Ugen K, Heller R. Electroporation for targeted gene transfer. Expert Opin Drug Deliv 2005; 2:255-68; PMID:16296752; http://dx.doi.org/10.1517/17425247.2.2.255
   PubMedGoogle Scholar
• Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J, Lewis M, Manischewitz J, King LR, Golding H, et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009; 83:4624-30; PMID:19211745; http://dx.doi.org/10.1128/JVI.02335-08
   PubMed Web of Science ®Google Scholar
• Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, Garcia-Hand D, Abdullah R, Braun R, Montefiori DC, et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007; 81:5257-69; PMID:17329330; http://dx.doi.org/10.1128/JVI.00055-07
   PubMed Web of Science ®Google Scholar
• Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6:508-14; PMID:10476210; http://dx.doi.org/10.1038/sj.gt.3300847
   PubMed Web of Science ®Google Scholar
• Otten G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J, O'Hagan D, Donnelly J, Widera G, et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004; 22:2489-93; PMID:15193413; http://dx.doi.org/10.1016/j.vaccine.2003.11.073
   PubMed Web of Science ®Google Scholar
• Scheerlinck JP, Karlis J, Tjelle TE, Presidente PJ, Mathiesen I, Newton SE. In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 2004; 22:1820-5; PMID:15068866; http://dx.doi.org/10.1016/j.vaccine.2003.09.053
   PubMed Web of Science ®Google Scholar
• Selby M, Goldbeck C, Pertile T, Walsh R, Ulmer J. Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000; 83:147-52; PMID:11000470; http://dx.doi.org/10.1016/S0168-1656(00)00308-4
   PubMed Web of Science ®Google Scholar
• Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, Leung L, Otten GR, Thudium K, Selby MJ, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164:4635-40; PMID:10779767; http://dx.doi.org/10.4049/jimmunol.164.9.4635
   PubMed Web of Science ®Google Scholar
• Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J Immunol 1997; 158:2278-84; PMID:9036975
   PubMed Web of Science ®Google Scholar
• Weiss R, Scheiblhofer S, Freund J, Ferreira F, Livey I, Thalhamer J. Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. Vaccine 2002; 20:3148-54; PMID:12163266; http://dx.doi.org/10.1016/S0264-410X(02)00250-5
   PubMed Web of Science ®Google Scholar
• Arrington J, Braun RP, Dong L, Fuller DH, Macklin MD, Umlauf SW, Wagner SJ, Wu MS, Payne LG, Haynes JR. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines. J Virol 2002; 76:4536-46; PMID:11932419; http://dx.doi.org/10.1128/JVI.76.9.4536-4546.2002
   PubMed Web of Science ®Google Scholar
• Babiuk LA, van Drunen Littel-van den H, Babiuk SL. Immunization of animals: from DNA to the dinner plate. Vet Immunol Immunopathol 1999; 72:189-202; PMID:10614509; http://dx.doi.org/10.1016/S0165-2427(99)00132-4
   PubMed Web of Science ®Google Scholar
• Haynes JR, Arrington J, Dong L, Braun RP, Payne LG. Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. Vaccine 2006; 24:5016-26; PMID:16621198; http://dx.doi.org/10.1016/j.vaccine.2006.03.046
   PubMed Web of Science ®Google Scholar
• Chow YH, Huang WL, Chi WK, Chu YD, Tao MH. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J Virol 1997; 71:169-78; PMID:8985336
   PubMed Web of Science ®Google Scholar
• Jang HS, Cho TH, Jang YS, Choung PH. Administration of multiple cytokine genes with anti-tumor activity inhibits both tumor incidence and tumor growth. Yonsei Med J 1999; 40:355-62; PMID:10487139; http://dx.doi.org/10.3349/ymj.1999.40.4.355
   PubMed Web of Science ®Google Scholar
• Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, et al. Modulation of amplitude and direction of in vivo immune responses by co- administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998; 28:1089-103; PMID:9541605; http://dx.doi.org/10.1002/(SICI)1521-4141(199803)28:03%3c1089::AID-IMMU1089%3e3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Kim JJ, Yang JS, Montaner L, Lee DJ, Chalian AA, Weiner DB. Coimmunization with IFN-gamma or IL-2, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo. J Interferon Cytokine Res 2000; 20:311-9; PMID:10762079; http://dx.doi.org/10.1089/10799900050023906
   PubMed Web of Science ®Google Scholar
• Sin JI, Kim JJ, Arnold RL, Shroff KE, McCallus D, Pachuk C, McElhiney SP, Wolf MW, Pompa-de BruinSJ, Higgins TJ, et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol 1999; 162:2912-21; PMID:10072541
   PubMed Web of Science ®Google Scholar
• Lu Y, Xin KQ, Hamajima K, Tsuji T, Aoki I, Yang J, Sasaki S, Fukushima J, Yoshimura T, Toda S, et al. Macrophage inflammatory protein-1alpha (MIP-1alpha) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin Exp Immunol 1999; 115:335-41; PMID:9933462; http://dx.doi.org/10.1046/j.1365-2249.1999.00793.x
   PubMed Web of Science ®Google Scholar
• Xin KQ, Lu Y, Hamajima K, Fukushima J, Yang J, Inamura K, Okuda K. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 1999; 92:90-6; PMID:10413656; http://dx.doi.org/10.1006/clim.1999.4730
   PubMed Web of Science ®Google Scholar
• Youssef S, Maor G, Wildbaum G, Grabie N, Gour-Lavie A, Karin N. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest 2000; 106:361-71; PMID:10930439; http://dx.doi.org/10.1172/JCI9109
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J Immunol 2005; 175:633-9; PMID:16002657; http://dx.doi.org/10.4049/jimmunol.175.2.633
   PubMed Web of Science ®Google Scholar
• Forde GM. Rapid-response vaccines–does DNA offer a solution? Nat Biotechnol 2005; 23:1059-62; PMID:16151391; http://dx.doi.org/10.1038/nbt0905-1059
   PubMed Web of Science ®Google Scholar
• Lu S, Wang S, Grimes-Serrano JM. Current progress of DNA vaccine studies in humans. Expert Rev Vaccines 2008; 7:175-91; PMID:18324888; http://dx.doi.org/10.1586/14760584.7.2.175
   PubMed Web of Science ®Google Scholar
• Chong SY, Egan MA, Kutzler MA, Megati S, Masood A, Roopchard V, Garcia-Hand D, Montefiori DC, Quiroz J, Rosati M, et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. Vaccine 2007; 25:4967-82; PMID:17335943; http://dx.doi.org/10.1016/j.vaccine.2006.11.070
   PubMed Web of Science ®Google Scholar
• Egan MA, Charini WA, Kuroda MJ, Schmitz JE, Racz P, Tenner-Racz K, Manson K, Wyand M, Lifton MA, Nickerson CE, et al. Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection. J Virol 2000; 74:7485-95; PMID:10906202; http://dx.doi.org/10.1128/JVI.74.16.7485-7495.2000
   PubMed Web of Science ®Google Scholar
• Egan MA, Chong SY, Megati S, Montefiori DC, Rose NF, Boyer JD, Sidhu MK, Quiroz J, Rosati M, Schadeck EB, et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 2005; 21:629-43; PMID:16060834; http://dx.doi.org/10.1089/aid.2005.21.629
   PubMed Web of Science ®Google Scholar
• Egan MA, Chong S-Y, Megati S, Montefiori DC, Rose NF, Sidhu M, Quiroz J, Schadeck EB, Pavlakis G, Weiner DB, et al. Priming with plasmid DNAs expressing IL-12 and SIV Gag protein enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 2005; 7:629-643; PMID:16060834; http://dx.doi.org/10.1089/aid.2005.21.629
   PubMed Web of Science ®Google Scholar
• Egan MA, Megati S, Roopchand V, Garcia-Hand D, Luckay A, Chong SY, Rosati M, Sackitey S, Weiner DB, Felber BK, et al. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine 2006; 24:4510-23; PMID:16140439; http://dx.doi.org/10.1016/j.vaccine.2005.08.024
   PubMed Web of Science ®Google Scholar
• Schadeck EB, Sidhu M, Egan MA, Chong SY, Piacente P, Masood A, Garcia-Hand D, Cappello S, Roopchand V, Megati S, et al. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine 2006; 24:4677-87; PMID:16288822; http://dx.doi.org/10.1016/j.vaccine.2005.10.035
   PubMed Web of Science ®Google Scholar
• Kalams S. Shocking results from HVTN 080. HVTN Conference. Seattle, WA: HIV Vaccine Trials Network, 2010.
   Google Scholar
• Bagley KC, Lewis GK, Fouts TR. The adjuvant activity of the catalytic A1 domain of cholera toxin for retroviral antigens delivered by GeneGun. Clin Vaccine Immunol 18, 922-930 (2011).
   Web of Science ®Google Scholar
• Bagley KC, Shata MT, Onyabe DY, DeVico AL, Fouts TR, Lewis GK, Hone DM. Immunogenicity of DNA vaccines that direct the coincident expression of the 120 kDa glycoprotein of human immunodeficiency virus and the catalytic domain of cholera toxin. Vaccine 2003; 21:3335-41; PMID:12804865; http://dx.doi.org/10.1016/S0264-410X(03)00038-0
   PubMed Web of Science ®Google Scholar
• Lycke N. The mechanism of cholera toxin adjuvanticity. Res Immunol 1997; 148:504-20; PMID:9588829; http://dx.doi.org/10.1016/S0923-2494(98)80144-2
   PubMedGoogle Scholar
• Ohtomo N, Muraoka T, Tashiro A, Zinnaka Y, Amako K. Size and structure of the cholera toxin molecule and its subunits. J Infect Dis 1976; 133 Suppl:31-40; PMID:815449; http://dx.doi.org/10.1093/infdis/133.Supplement_1.S31
   PubMedGoogle Scholar
• Heyningen SV. Cholera toxin: interaction of subunits with ganglioside GM1. Science 1974; 183:656-7; PMID:4810267; http://dx.doi.org/10.1126/science.183.4125.656
   PubMed Web of Science ®Google Scholar
• Hazes B, Read RJ. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 1997; 36:11051-4; PMID:9333321; http://dx.doi.org/10.1021/bi971383p
   PubMed Web of Science ®Google Scholar
• Cassel D, Selinger Z. Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site. Proc Natl Acad Sci U S A 1977; 74:3307-11; PMID:198781; http://dx.doi.org/10.1073/pnas.74.8.3307
   PubMed Web of Science ®Google Scholar
• Agren L, Lowenadler B, Lycke N. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit. Immunology and cell biology 1998; 76:280-7; PMID:9682972; http://dx.doi.org/10.1046/j.1440-1711.1998.00750.x
   PubMed Web of Science ®Google Scholar
• Agren L, Sverremark E, Ekman L, Schon K, Lowenadler B, Fernandez C, Lycke N. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti- apoptotic Bcl-2- and germinal center-promoting effects. J Immunol 2000; 164:6276-86; PMID:10843681; http://dx.doi.org/10.4049/jimmunol.164.12.6276
   PubMed Web of Science ®Google Scholar
• Bagley KC, Abdelwahab SF, Tuskan RG, Fouts TR, Lewis GK. Cholera Toxin and Heat-Labile Enterotoxin Activate Human Monocyte- Derived Dendritic Cells and Dominantly Inhibit Cytokine Production through a Cyclic AMP-Dependent Pathway. Infect Immun 2002; 70:5533-9; PMID:12228279; http://dx.doi.org/10.1128/IAI.70.10.5533-5539.2002
   PubMed Web of Science ®Google Scholar
• Bagley KC, Abdelwahab SF, Tuskan RG, Lewis GK. An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants. Infect Immun 2003; 71:6850-6; PMID:14638772; http://dx.doi.org/10.1128/IAI.71.12.6850-6856.2003
   PubMed Web of Science ®Google Scholar
• Giuliani MM, Del Giudice G, Giannelli V, Dougan G, Douce G, Rappuoli R, Pizza M. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med 1998; 187:1123-32; PMID:9529328; http://dx.doi.org/10.1084/jem.187.7.1123
   PubMed Web of Science ®Google Scholar
• Lycke N, Tsuji T, Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 1992; 22:2277-81; PMID:1381311; http://dx.doi.org/10.1002/eji.1830220915
   PubMed Web of Science ®Google Scholar
• Ryan EJ, McNeela E, Pizza M, Rappuoli R, O'Neill L, Mills KH. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity. J Immunol 2000; 165:5750-9; PMID:11067933; http://dx.doi.org/10.4049/jimmunol.165.10.5750
   PubMed Web of Science ®Google Scholar
• De Haan L, Hirst TR. Cholera toxin: a paradigm for multi-functional engagement of cellular mechanisms (Review). Mol Membr Biol 2004; 21:77-92; PMID:15204437; http://dx.doi.org/10.1080/09687680410001663267
   PubMed Web of Science ®Google Scholar
• Morinaga N, Kaihou Y, Vitale N, Moss J, Noda M. Involvement of ADP-ribosylation factor 1 in cholera toxin-induced morphological changes of Chinese hamster ovary cells. J Biol Chem 2001; 276:22838-43; PMID:11279243; http://dx.doi.org/10.1074/jbc.M101184200
   PubMed Web of Science ®Google Scholar
• Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera. Nature 1981; 292:413-17; PMID:7019725; http://dx.doi.org/10.1038/292413a0
   PubMed Web of Science ®Google Scholar
• Douce G, Turcotte C, Cropley I, Roberts M, Pizza M, Domenghini M, Rappuoli R, Dougan G. Mutants of Escherichia coli heat-labile toxin lacking ADP- ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci U S A 1995; 92:1644-8; PMID:7878032; http://dx.doi.org/10.1073/pnas.92.5.1644
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Takeda Y, Yamamoto M, Kurazono H, Imaoka K, Fujihashi K, Noda M, Kiyono H, McGhee JR. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med 1997; 185:1203-10; PMID:9104807; http://dx.doi.org/10.1084/jem.185.7.1203
   PubMed Web of Science ®Google Scholar
• Pizza M, Giuliani MM, Fontana MR, Douce G, Dougan G, Rappuoli R. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials. Int J Med Microbiol 2000; 290:455-61; PMID:11111926; http://dx.doi.org/10.1016/S1438-4221(00)80064-8
   PubMed Web of Science ®Google Scholar
• Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, Seid RC, Yu J. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 2007; 6:809-19; PMID:17931160; http://dx.doi.org/10.1586/14760584.6.5.809
   PubMed Web of Science ®Google Scholar
• Glenn GM, Rao M, Matyas GR, Alving CR. Skin immunization made possible by cholera toxin. Nature 1998; 391:851; PMID:9495336; http://dx.doi.org/10.1038/36014
   PubMed Web of Science ®Google Scholar
• Glenn GM, Scharton-Kersten T, Vassell R, Mallett CP, Hale TL, Alving CR. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J Immunol 1998; 161:3211-4; PMID:9759833
   PubMed Web of Science ®Google Scholar
• Glenn GM, Scharton-Kersten T, Vassell R, Matyas GR, Alving CR. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999; 67:1100-6; PMID:10024549
   PubMed Web of Science ®Google Scholar
• Glenn GM, Taylor DN, Li X, Frankel S, Montemarano A, Alving CR. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat Med 2000; 6:1403-6; PMID:11100128; http://dx.doi.org/10.1038/82225
   PubMed Web of Science ®Google Scholar
• Brereton CF, Sutton CE, Ross PJ, Iwakura Y, Pizza M, Rappuoli R, Lavelle EC, Mills KH. Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol 2011; 186:5896-906; PMID:21490151; http://dx.doi.org/10.4049/jimmunol.1003789
   PubMed Web of Science ®Google Scholar
• Datta SK, Sabet M, Nguyen KP, Valdez PA, Gonzalez-Navajas JM, Islam S, Mihajlov I, Fierer J, Insel PA, Webster NJ, et al. Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc Natl Acad Sci U S A 2010; 107:10638-43; PMID:20479237; http://dx.doi.org/10.1073/pnas.1002348107
   PubMed Web of Science ®Google Scholar
• Lee JB, Jang JE, Song MK, Chang J. Intranasal delivery of cholera toxin induces th17-dominated T-cell response to bystander antigens. PLoS One 2009; 4:e5190; PMID:19360100; http://dx.doi.org/10.1371/journal.pone.0005190
   PubMed Web of Science ®Google Scholar
• Norton EB, Lawson LB, Mahdi Z, Freytag LC, Clements JD. The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens. Infect Immun 2012; 80:2426-35; PMID:22526674; http://dx.doi.org/10.1128/IAI.00181-12
   PubMed Web of Science ®Google Scholar
• Nedrud JG, Bagheri N, Schon K, Xin W, Bergroth H, Eliasson DG, Lycke NY. Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity. PLoS One 2013; 8:e83321
   PubMed Web of Science ®Google Scholar
• Gehl J, Mir LM. Determination of optimal parameters for in vivo gene transfer by electroporation, using a rapid in vivo test for cell permeabilization. Biochem Biophys Res Commun 1999; 261:377-80; PMID:10425193; http://dx.doi.org/10.1006/bbrc.1999.1014
   PubMed Web of Science ®Google Scholar
• Bachy M, Boudet F, Bureau M, Girerd-Chambaz Y, Wils P, Scherman D, Meric C. Electric pulses increase the immunogenicity of an influenza DNA vaccine injected intramuscularly in the mouse. Vaccine 2001; 19:1688-93; PMID:11166892; http://dx.doi.org/10.1016/S0264-410X(00)00406-0
   PubMed Web of Science ®Google Scholar
• Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a “prime/boost” strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005; 174:6292-8; PMID:15879128; http://dx.doi.org/10.4049/jimmunol.174.10.6292
   PubMed Web of Science ®Google Scholar
• Tollefsen S, Vordermeier M, Olsen I, Storset AK, Reitan LJ, Clifford D, Lowrie DB, Wiker HG, Huygen K, Hewinson G, et al. DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. Scand J Immunol 2003; 57:229-38; PMID:12641651; http://dx.doi.org/10.1046/j.1365-3083.2003.01218.x
   PubMed Web of Science ®Google Scholar
• Zhao YG, Peng B, Deng H, Chen G, Yang F, Shao M, Lu H, Li Y, Peng J, Xu L, et al. Anti-HBV immune responses in rhesus macaques elicited by electroporation mediated DNA vaccination. Vaccine 2006; 24:897-903; PMID:16253404; http://dx.doi.org/10.1016/j.vaccine.2005.08.093
   PubMed Web of Science ®Google Scholar
• Zucchelli S, Capone S, Fattori E, Folgori A, Di Marco A, Casimiro D, Simon AJ, Laufer R, La Monica N, Cortese R, et al. Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer. J Virol 2000; 74:11598-607; PMID:11090158; http://dx.doi.org/10.1128/JVI.74.24.11598-11607.2000
   PubMed Web of Science ®Google Scholar
• Belladonna ML, Renauld JC, Bianchi R, Vacca C, Fallarino F, Orabona C, Fioretti MC, Grohmann U, Puccetti P. IL-23 and IL-12 have overlapping, but distinct, effects on murine dendritic cells. J Immunol 2002; 168:5448-54; PMID:12023338; http://dx.doi.org/10.4049/jimmunol.168.11.5448
   PubMed Web of Science ®Google Scholar
• Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009; 8:40-52; PMID:19275692; http://dx.doi.org/10.2174/187152809787582507
   PubMedGoogle Scholar
• Grohmann U, Belladonna ML, Vacca C, Bianchi R, Fallarino F, Orabona C, Fioretti MC, Puccetti P. Positive regulatory role of IL-12 in macrophages and modulation by IFN-gamma. J Immunol 2001; 167:221-7; PMID:11418652; http://dx.doi.org/10.4049/jimmunol.167.1.221
   PubMed Web of Science ®Google Scholar
• Langrish CL, McKenzie BS, Wilson NJ, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev 2004; 202:96-105; PMID:15546388; http://dx.doi.org/10.1111/j.0105-2896.2004.00214.x
   PubMed Web of Science ®Google Scholar
• Novelli F, Casanova JL. The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev 2004; 15:367-77; PMID:15450252; http://dx.doi.org/10.1016/j.cytogfr.2004.03.009
   PubMed Web of Science ®Google Scholar
• Ryffel B. Interleukin-12: role of interferon-gamma in IL-12 adverse effects. Clin Immunol Immunopathol 1997; 83:18-20; PMID:9073529; http://dx.doi.org/10.1006/clin.1996.4306
   PubMedGoogle Scholar
• Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, Jackson SS, Lifton MA, Freed DC, Perry HC, et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 2002; 168:562-8; PMID:11777947; http://dx.doi.org/10.4049/jimmunol.168.2.562
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Stiernholm BJ, Chan AK, Berinstein NL, Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997; 158:4591-601; PMID:9144471
   PubMed Web of Science ®Google Scholar
• Kim JJ, Simbiri KA, Sin JI, Dang K, Oh J, Dentchev T, Lee D, Nottingham LK, Chalian AA, McCallus D, et al. Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res 1999; 19:77-84; PMID:10048771; http://dx.doi.org/10.1089/107999099314441
   PubMed Web of Science ®Google Scholar
• Lai L, Vodros D, Kozlowski PA, Montefiori DC, Wilson RL, Akerstrom VL, Chennareddi L, Yu T, Kannanganat S, Ofielu L, et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 2007; 369:153-67; PMID:17698160; http://dx.doi.org/10.1016/j.virol.2007.07.017
   PubMed Web of Science ®Google Scholar
• Fukuta S, Magnani JL, Twiddy EM, Holmes RK, Ginsburg V. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTh-I, LT-IIa, and LT-IIb. Infect Immun 1988; 56:1748-53; PMID:3290106
   PubMed Web of Science ®Google Scholar
• Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005; 23:1804-13; PMID:15734046; http://dx.doi.org/10.1016/j.vaccine.2004.11.010
   PubMed Web of Science ®Google Scholar
• Afonina IS, Cullen SP, Martin SJ. Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol Rev 2010; 235:105-16; PMID:20536558
   PubMed Web of Science ®Google Scholar
• Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: a natural born killer. Immunol Rev 2003; 193:31-8; PMID:12752668; http://dx.doi.org/10.1034/j.1600-065X.2003.00044.x
   PubMed Web of Science ®Google Scholar
• Shresta S, Heusel JW, Macivor DM, Wesselschmidt RL, Russell JH, Ley TJ. Granzyme B plays a critical role in cytotoxic lymphocyte-induced apoptosis. Immunol Rev 1995; 146:211-21; PMID:7493755; http://dx.doi.org/10.1111/j.1600-065X.1995.tb00690.x
   PubMed Web of Science ®Google Scholar
• Liu MA. DNA vaccines: a review. J Intern Med 2003; 253:402-10; PMID:12653868; http://dx.doi.org/10.1046/j.1365-2796.2003.01140.x
   PubMed Web of Science ®Google Scholar
• Jones S, Evans K, McElwaine-Johnn H, Sharpe M, Oxford J, Lambkin-Williams R, Mant T, Nolan A, Zambon M, Ellis J, et al. DNA vaccination protects against an influenza challenge in a double-blind randomised placebo-controlled phase 1b clinical trial. Vaccine 2009; 27:2506-12; PMID:19368793; http://dx.doi.org/10.1016/j.vaccine.2009.02.061
   PubMed Web of Science ®Google Scholar
• Sharpe M, Lynch D, Topham S, Major D, Wood J, Loudon P. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine 2007; 25:6392-8; PMID:17640779; http://dx.doi.org/10.1016/j.vaccine.2007.06.009
   PubMed Web of Science ®Google Scholar
• Fuller DH, Rajakumar P, Che JW, Narendran A, Nyaundi J, Michael H, Yager EJ, Stagnar C, Wahlberg B, Taber R, et al. Therapeutic DNA vaccine induces broad T cell responses in the gut and sustained protection from viral rebound and AIDS in SIV-infected rhesus macaques. PLoS One 2012; 7:e33715; PMID:22442716; http://dx.doi.org/10.1371/journal.pone.0033715
   PubMed Web of Science ®Google Scholar
• Yager EJ, Dean HJ, Fuller DH. Prospects for developing an effective particle-mediated DNA vaccine against influenza. Expert Rev Vaccines 2009; 8:1205-20; PMID:19722894; http://dx.doi.org/10.1586/erv.09.82
   PubMed Web of Science ®Google Scholar
• Yager EJ, Stagnar C, Gopalakrishnan R, Fuller JT, Fuller DH. Optimizing particle-mediated epidermal delivery of an influenza DNA vaccine in ferrets. Methods Mol Biol 2013; 940:223-37; PMID:23104347
   PubMedGoogle Scholar
• Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, Parkinson R, Wu L, Sidhu MK, Pavlakis GN, et al. Protection against simian/human immunodeficiency virus (SHIV) 89.6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc Natl Acad Sci U S A 2007; 104:18648-53; PMID:18000037; http://dx.doi.org/10.1073/pnas.0709198104
   PubMed Web of Science ®Google Scholar
• Halwani R, Boyer JD, Yassine-Diab B, Haddad EK, Robinson TM, Kumar S, Parkinson R, Wu L, Sidhu MK, Phillipson-Weiner R, et al. Therapeutic vaccination with simian immunodeficiency virus (SIV)-DNA + IL-12 or IL-15 induces distinct CD8 memory subsets in SIV-infected macaques. J Immunol 2008; 180:7969-79; PMID:18523260; http://dx.doi.org/10.4049/jimmunol.180.12.7969
   PubMed Web of Science ®Google Scholar
• Hung CF, Monie A, Alvarez RD, Wu TC. DNA vaccines for cervical cancer: from bench to bedside. Exp Mol Med 2007; 39:679-89; PMID:18160838; http://dx.doi.org/10.1038/emm.2007.74
   PubMed Web of Science ®Google Scholar
• Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res 2009; 15:361-7; PMID:19118066; http://dx.doi.org/10.1158/1078-0432.CCR-08-1725
   PubMed Web of Science ®Google Scholar
• Zeng Q, Peng S, Monie A, Yang M, Pang X, Hung CF, Wu TC. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther 2011; 22:809-19; PMID:21128743; http://dx.doi.org/10.1089/hum.2010.071
   PubMed Web of Science ®Google Scholar
• Gherardi MM, Ramirez JC, Esteban M. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol 2000; 74:6278-86; PMID:10864637; http://dx.doi.org/10.1128/JVI.74.14.6278-6286.2000
   PubMed Web of Science ®Google Scholar
• Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, McClanahan T, Kastelein RA, Cua DJ. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233-40; PMID:15657292; http://dx.doi.org/10.1084/jem.20041257
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1123-32; PMID:16200070; http://dx.doi.org/10.1038/ni1254
   PubMed Web of Science ®Google Scholar
• Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, et al. A distinct lineage of CD4T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005; 6:1133-41; PMID:16200068; http://dx.doi.org/10.1038/ni1261
   PubMed Web of Science ®Google Scholar
• Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007; 448:480-3; PMID:17581589; http://dx.doi.org/10.1038/nature05969
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, Oukka M, Kuchroo VK. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448:484-7; PMID:17581588; http://dx.doi.org/10.1038/nature05970
   PubMed Web of Science ®Google Scholar
• Chung Y, Yang X, Chang SH, Ma L, Tian Q, Dong C. Expression and regulation of IL-22 in the IL-17-producing CD4+ T lymphocytes. Cell Res 2006; 16:902-7; PMID:17088898; http://dx.doi.org/10.1038/sj.cr.7310106
   PubMed Web of Science ®Google Scholar
• Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, Fouser LA. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203:2271-9; PMID:16982811; http://dx.doi.org/10.1084/jem.20061308
   PubMed Web of Science ®Google Scholar
• Basu R, Hatton RD, Weaver CT. The Th17 family: flexibility follows function. Immunol Rev 2013; 252:89-103; PMID:23405897; http://dx.doi.org/10.1111/imr.12035
   PubMed Web of Science ®Google Scholar
• Mitsdoerffer M, Lee Y, Jager A, Kim HJ, Korn T, Kolls JK, Cantor H, Bettelli E, Kuchroo VK. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A 2010; 107:14292-7; PMID:20660725; http://dx.doi.org/10.1073/pnas.1009234107
   PubMed Web of Science ®Google Scholar
• Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223:87-113; PMID:18613831; http://dx.doi.org/10.1111/j.1600-065X.2008.00628.x
   PubMed Web of Science ®Google Scholar
• Ye J, Livergood RS, Peng G. The role and regulation of human Th17 cells in tumor immunity. Am J Pathol 2013; 182:10-20; PMID:23159950; http://dx.doi.org/10.1016/j.ajpath.2012.08.041
   PubMed Web of Science ®Google Scholar
• Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, Ahlfors H, Wilhelm C, Tolaini M, Menzel U, et al. Fate mapping of IL-17-producing T cells in inflammatory responses. Nat Immunol 2011; 12:255-63; PMID:21278737; http://dx.doi.org/10.1038/ni.1993
   PubMed Web of Science ®Google Scholar
• Kumar P, Chen K, Kolls JK. Th17 cell based vaccines in mucosal immunity. Curr Opin Immunol 2013; 25:373-80; PMID:23669353; http://dx.doi.org/10.1016/j.coi.2013.03.011
   PubMed Web of Science ®Google Scholar
• Agren L, Norin M, Lycke N, Lowenadler B. Hydrophobicity engineering of cholera toxin A1 subunit in the strong adjuvant fusion protein CTA1-DD. Protein Eng 1999; 12:173-8; PMID:10195289; http://dx.doi.org/10.1093/protein/12.2.173
   PubMedGoogle Scholar
• Lycke N. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell Microbiol 2004; 6:23-32; PMID:14678328; http://dx.doi.org/10.1046/j.1462-5822.2003.00338.x
   PubMed Web of Science ®Google Scholar
• Moore JP, Jarrett RF. Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1. AIDS Res Hum Retroviruses 1988; 4:369-79; PMID:2848557; http://dx.doi.org/10.1089/aid.1988.4.369
   PubMed Web of Science ®Google Scholar
• Moore JP, McKeating JA, Jones IM, Stephens PE, Clements G, Thomson S, Weiss RA. Characterisation of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and sCD4. AIDS 1990; 4:307-15; PMID:2190605; http://dx.doi.org/10.1097/00002030-199004000-00004
   PubMed Web of Science ®Google Scholar